Trademark: 97524671
Word
ZEPHYR AI
Status
Pending
Status Code
730
Status Date
Friday, May 3, 2024
Serial Number
97524671
Mark Type
4
Filing Date
Thursday, July 28, 2022
Published for Opposition
Tuesday, September 26, 2023

Trademark Owner History
Zephyr AI, Inc - Owner At Publication

Classifications
9 Downloadable computer programs using artificial intelligence for machine learning; downloadable software using artificial intelligence for machine learning for scientific and medical research and development; downloadable computer software, software platforms, downloadable mobile applications, and downloadable software programs using artificial intelligence and machine learning technologies for scientific and medical research and development; downloadable computer programs using artificial intelligence for machine learning in the fields of healthcare, medicine, genetics, oncology, biology, life sciences, biotechnology, drug development, and pharmaceuticals
44 Healthcare;medical services;consulting services in the field of healthcare, medicine, and medical use of pharmaceuticals; healthcare, medical, and pharmaceutical medical use information services; DNA screening for medical purposes; clinical medical consultation services; healthcare, medical, and pharmaceutical services, namely, providing databases in the fields of medical, scientific, genetic, oncological, and biological information for inputting, collecting, analyzing, and managing data for treatment and diagnostic purposes; healthcare and medical services, namely, analyzing medical, genetic, oncological, biological and diabetes-related data for treatment and diagnostic purposes by using machine learning and artificial intelligence technologies; providing medical consulting services in the fields of healthcare, medicine, genetics, oncology, biology, life sciences, biotechnology, drug development, and pharmaceuticals by using machine learning, artificial intelligence technology, and biotechnology
42 Scientific research consulting services in the fields of healthcare, medicine, genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; scientific and medical research analysis of healthcare, medical, genetic, scientific, biologic, clinical and oncologic data; scientific research consulting in the fields of healthcare, medicine, genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; genetic and tumor mapping for scientific and medical research purposes; providing medical and scientific research information in the fields of genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; drug discovery services; scientific services, namely, analyzing medical, genetic, oncological, biological and diabetes-related data for treatment and diagnostic purposes by using machine learning and artificial intelligence technologies; providing scientific, medical and clinical research and scientific, medical and clinical research consulting services in the fields of healthcare, medicine, genetics, oncology, biology, life sciences, biotechnology, drug development, and pharmaceuticals by using machine learning, artificial intelligence technology, and biotechnology; medical and scientific research and consulting, namely, designing and organizing clinical trials for others; research and development services in the creation of databases and collections of information and data on biologicals for research purposes; providing genetic reference databases being collections of gene sequences for research purposes; disease modeling for research purposes; scientific analysis services, namely, services using computer algorithms for analysis of bioinformatics data in the field of research and development of therapeutic biomolecules for the treatment of cancer, diabetes, and other diseases; pharmaceutical drug development services; genetic research for identifying biomarker rankings for medical purposes; research and development of pharmaceutical preparations and medicines; consulting services in the field of pharmaceutical research and development; medical and scientific research in the field of medical treatment and diagnosis, including for cancer and diabetes; providing temporary use of online non-downloadable software, cloud-based software, platform as a service (PAAS) featuring computer software platforms, and a website featuring technology, all for enabling users to use artificial intelligence for machine learning in the fields of healthcare, medicine, genetics, oncology, diabetes, biology, life sciences, biotechnology, drug development, and pharmaceuticals; software design and development; software installation and maintenance; DNA analysis services for scientific and medical research purposes; application service provider (ASP) featuring software using artificial intelligence for machine learning
"AI"

Trademark Events
Aug 1, 2022
New Application Entered
Aug 1, 2022
New Application Office Supplied Data Entered
May 15, 2023
Assigned To Examiner
May 17, 2023
Non-Final Action Written
May 17, 2023
Non-Final Action E-Mailed
May 17, 2023
Notification Of Non-Final Action E-Mailed
Jun 13, 2023
Teas Response To Office Action Received
Jun 13, 2023
Correspondence Received In Law Office
Jun 14, 2023
Teas/Email Correspondence Entered
Aug 22, 2023
Notification Of Examiners Amendment E-Mailed
Aug 14, 2023
Final Refusal Written
Aug 14, 2023
Final Refusal E-Mailed
Aug 14, 2023
Notification Of Final Refusal Emailed
Aug 22, 2023
Examiners Amendment -Written
Aug 22, 2023
Examiners Amendment E-Mailed
Aug 22, 2023
Examiner's Amendment Entered
Aug 22, 2023
Approved For Pub - Principal Register
Sep 6, 2023
Notification Of Notice Of Publication E-Mailed
Sep 26, 2023
Published For Opposition
Sep 26, 2023
Official Gazette Publication Confirmation E-Mailed
Feb 22, 2024
Teas Change Of Correspondence Received
Nov 21, 2023
Noa E-Mailed - Sou Required From Applicant
Feb 22, 2024
Attorney/Dom.Rep.Revoked And/Or Appointed
Feb 22, 2024
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Feb 22, 2024
Teas Withdrawal Of Attorney Received-Firm Retains
May 3, 2024
Sou Teas Extension Received
May 3, 2024
Sou Extension 1 Filed
May 3, 2024
Sou Extension 1 Granted
May 4, 2024
Notice Of Approval Of Extension Request E-Mailed

Trademark Alertz updated from USPTO on 2030-01-24